The Medical Imaging & Technology Alliance (MITA)—the trade association representing manufacturers of medical imaging equipment, radiopharmaceuticals, contrast media, and focused ultrasound therapeutic devices—has submitted comments to United States Preventive Services Task Force (USPSTF) on its draft recommendation on breast cancer screening.
In its comments, MITA notes, “We applaud the task force for lowering the recommended screening start age from 50 to 40. We remain concerned, however, that this draft recommendation may be inadequate, and will not align with current clinical guidelines.” The comments go on to recommend that USPSTF review the guidelines of other expert groups as well as adopt open and transparent research methodologies for its assessment of breast cancer screening.
“We must do more to promote access and adherence to screening exams, which can lead to early and more effective treatment that ultimately saves lives,” adds Patrick Hope, executive director of MITA. “Clear and transparent USPSTF guidance that aligns with those of relevant clinical professional societies will go a long way to help to reduce breast cancer mortality and improve outcomes for patients.”
To view MITA’s full comments to USPSTF, click here.
